{"entity":{"id":"sunshine-lake-pharma","kind":"company","name":"Sunshine Lake Pharma (HEC)","aka":["Sunshine Lake Pharma Co., Ltd.","HEC Pharm"],"tldr":"Sunshine Lake Pharma, the pharmaceutical arm of China's HEC group based in Dongguan, is running phase 3 trials of clifutinib, a FLT3 inhibitor for acute myeloid leukaemia, and lerotinib in oesophageal cancer.","summary":"Sunshine Lake Pharma, part of the HEC (Dongyangguang) group in Dongguan, Guangdong, is a Chinese pharmaceutical company with antiviral, metabolic and oncology pipelines. In cancer it is developing clifutinib, a small-molecule FLT3 inhibitor in a phase 3 trial for FLT3-mutated acute myeloid leukaemia, and lerotinib, a small-molecule kinase inhibitor in a phase 3 trial for oesophageal cancer. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the group website.","asOf":"2026-09-11","links":[{"label":"HEC group website","url":"https://www.hec.cn/"},{"label":"ClinicalTrials.gov: trials led by Sunshine Lake Pharma","url":"https://clinicaltrials.gov/search?lead=Sunshine%20Lake%20Pharma"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml","esophageal"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["clifutinib","lerotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05586074","nct04415853","nct05133882","nct05451602"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Dongguan","country":"CN","companyType":"pharma","website":"https://www.hec.cn/","stage":"public","investors":[],"funding":[]},"route":"/companies/sunshine-lake-pharma/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"clifutinib","kind":"drug","name":"Clifutinib","route":"/drugs/clifutinib/"},{"id":"lerotinib","kind":"drug","name":"Lerotinib","route":"/drugs/lerotinib/"}],"trial":[{"id":"nct05133882","kind":"trial","name":"A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML","route":"/trials/nct05133882/"},{"id":"nct05451602","kind":"trial","name":"HEC169096 in Participants With Advanced Solid Tumors","route":"/trials/nct05451602/"},{"id":"nct05586074","kind":"trial","name":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","route":"/trials/nct05586074/"},{"id":"nct04415853","kind":"trial","name":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","route":"/trials/nct04415853/"}]}}